SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following robust positive Phase 2 data for sonelokimab in axial spondyloarthritis, highlighting an 81% ASAS40 response and suggesting disease-modifying potential. The community is eagerly discussing this strong clinical validation, coupled with a solid financial position and significant institutional share repurchases, fueling anticipation for a potential short squeeze and re-valuation ahead of its upcoming Investor Day.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid fresh market uncertainty as new global tariffs announced by Trump following a Supreme Court ruling are sparking concerns over potential trade friction with allies like the EU and India. This sentiment is amplified by a significant pullback in Bitcoin, which some in the community see as a broader signal of financial system stress, with many actively debating whether the market will recover or face a deeper correction ahead of NVIDIA's crucial earnings report this week.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant downward pressure from geopolitical tensions, particularly surrounding new tariff threats and potential international conflicts, combined with aggressive "whale" selling that has broken key support levels. This confluence of events is fueling a sharp community debate, with bears pointing to ongoing market manipulation and even conspiratorial links as reasons for further declines, while bulls advocate for buying the dip amidst a recurring pattern of weekend sell-offs.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending due to its exceptionally active and resilient community, which is relentlessly building a permissionless brand through 20+ real-world initiatives like energy drinks and street art. This strong collective conviction, emphasizing continuous building and 'buying the dip' even in a down market, positions Kendu as a unique long-term play in the crypto space.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is drawing attention following reports of significant ETF inflows and its strategic shift to scale traditional finance on-chain. The community is sharply divided, with proponents advocating to buy dips and stake amid regulatory optimism, while skeptics foresee further downside for the asset.

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network (SNX) is trending due to community excitement surrounding its expanded presence on major platforms, the highly anticipated $1 million trading competition, and the launch of its Perps V3 on Ethereum Mainnet, alongside notable updates to its tokenomics.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing intense community debate as long-term holders actively accumulate at what they consider generational lows, citing ongoing developments like new integrations and post-quantum secure transactions. Conversely, persistent bearish sentiment focuses on historical underperformance and concerns regarding the Algorand Foundation's management, with some predicting further price decline despite broader market discussions around an altcoin season and regulatory clarity.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is trending as the crypto community actively buys perceived dips, fueled by strong HODLing sentiment and anticipation of a broader meme coin season. Many are discussing "loading the boat" and awaiting a significant price run, often using the "feels good man" meme.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is trending due to accelerating hyperscale orders for its 800G transceivers, notably from Amazon, alongside plans to significantly expand its AI data center manufacturing. The community is buzzing about potential short squeezes and higher price targets as the optical components sector plays a crucial role in AI infrastructure buildouts.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is sparking intense debate following its earnings report, where the company announced a beta mortgage product and projected adjusted EBITDA profitability by Q2, electrifying bulls confident in its AI and capital-light transformation while bears remain skeptical of persistent losses and the iBuying model's viability amidst market volatility.

statis crypto Watchlist

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Brookline Cap M Weighs in on iBio's Q3 Earnings (NYSE:IBIO)

iBio, Inc. (NYSE:IBIO - Free Report) - Stock analysts at Brookline Cap M raised their Q3 2026 earnings estimates for shares of iBio in a report issued on Wednesday, February 11th. Brookline Cap M...

iBio (NASDAQ:IBIO) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut shares of iBio from a "hold" rating to a "sell" rating in a research note on Saturday...

iBio Earnings Review: Q2 Summary

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?

CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

iBio (NASDAQ:IBIO) Stock Price Down 3.6% - Here's Why

iBio (NASDAQ:IBIO) Trading Down 3.6% - What's Next...

<ul class="summary-bullets"><li>iBio intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs.</li><li>This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.</li><li>The company also stated that it will use the funds to continue to progress other preclinical assets in the pipeline.</li></ul>Shares of iBio Inc. (IBIO) surged more than 12% in Friday’s pre-market trade after the company announced a private placement of securities worth $26 million.In its announcement, iBio stated that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality institutional investors for private placement financing. It expects the offering to close on or about Jan. 13, 2026, subject to customary closing conditions.iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.<h2 class="st-heading-2">Here’s What iBio Intends To Use Funds For</h2>In its announcement, iBio noted that it intends to use the proceeds from the private placement toward advancing its preclinical cardiometabolic programs. This includes the IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs.Additionally, iBio said it will use the funds to advance other preclinical assets in the pipeline. The balance, if any, would be used toward meeting the company’s working capital requirements, iBio stated.The company added that the $26 million private placement extends its cash runway into 2028. It is also worth nearly 50% of iBio’s current market capitalization, which stood at nearly $53 million on Thursday.<h2 class="st-heading-2">What Does iBio Do?</h2>iBio is a San Diego, California-based company that is working on the development of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function.The company states that current GLP-1 treatments result in muscle loss in addition to fat loss. However, its therapeutic candidates for cardiometabolic diseases and obesity aim to preserve and build muscle mass during weight loss.iBio says it uses its patented artificial intelligence and machine learning platform to accelerate the discovery of novel therapies for obesity and cardiometabolic disorders.<h2 class="st-heading-2">Here’s What Stocktwits Users Think</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/IBIO">iBio</a> trended in the ‘neutral’ territory at the time of writing.One user on the platform stated that the private placement is “bullish” news for the company, and that the “science here intrigues the industry.”<stembedurl>https://stocktwits.com/MiltonMilkyMilkovich/message/641313031</stembedurl><a href="https://stocktwits.com/symbol/IBIO">IBIO stock</a> is up 22% year-to-date, but down 14% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/what-is-fueling-smr-stock-surge-today/cmU2QIKR4dB">What Is Fueling SMR Stock's Surge Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement

iBio stated that it is selling more than 11 million shares of its common stock at a purchase price of $2.35 apiece.

Equity

Best Penny Stocks To Consider - December 10th

iBio, iBio, Momentus, Bitfarms, Richtech Robotics, Bit Digital, and Strive are the seven Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares...

Top Manufacturing Stocks To Keep An Eye On - December 10th

Taiwan Semiconductor Manufacturing, Applied Materials, Johnson Controls International, Flex, iBio, FREYR Battery, and Fabrinet are the seven Manufacturing stocks to watch today, according to...

Manufacturing Stocks To Research - December 8th

Taiwan Semiconductor Manufacturing, Applied Materials, Flex, Johnson Controls International, and iBio are the five Manufacturing stocks to watch today, according to MarketBeat's stock screener tool...

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Current Price	$2.38
Prev Close	$2.45
Open	$2.40
Dividend Yield	0.00%
50-Day Moving Average	$2.19
Beta	1.24
Avg. Volume	3.02M
PE Ratio	-2.37

52-Week High	$6.89
52-Week Low	$0.5562
Market Capitalization	$82.21M
EPS (Annual)	-$1.75
Price to Book	1.26
Revenue Per Employee	$20,000.00

IBIO
iBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBIO News

IBIOiBio Inc